Article
Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastoma
2026-04-17
Abstract excerpt
<title>Abstract</title> <p>Glioblastoma (GBM) is characterized by aberrant neovascularization and angiogenesis. Bevacizumab (Avastin), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is clinically used with chemotherapy for patients with GBM, yet its impact on the tumor immune microenvironment remains poorly understood. Transcriptomic profiling of matched pre- and post-treatment tumors...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ff7331e3-1145-5db5-b031-d055bfcb447a
- DOI
- 10.21203/rs.3.rs-9350019/v1
